Scientists map more than 1,000 overlooked brain proteins, tying one to Alzheimer's

Scientists at the Salk Institute for Biological Studies have built the first detailed atlas of "microproteins" in the human brain, cataloging more than a thousand tiny, previously undocumented molecules and tying one of them to a breakdown in the energy supply of brain immune cells affected by Alzheimer's disease.

The study, published Monday in Nature Aging, drew on 480 postmortem samples of the frontal cortex, roughly half from people who had Alzheimer's disease and half from those who did not. Using an artificial-intelligence tool built in-house, the researchers combed through genetic and protein data that standard genome-annotation methods routinely discard, and surfaced 1,067 microproteins that had never before been documented in human tissue.

What the numbers show

Microproteins are short chains of amino acids, generally fewer than 150, that are made from stretches of DNA long classified as "junk" because they were considered too short to code for anything useful. Standard gene-finding software is typically tuned to ignore genetic sequences below a certain length, on the assumption that true genes are longer. That assumption, researchers say, has left an entire layer of biology poorly mapped for decades, even as sequencing and mass-spectrometry technology improved enough to detect the tiny fragments themselves.

In the new atlas, described in a Salk Institute release distributed through EurekAlert, hundreds of the newly identified microproteins were expressed at different levels in Alzheimer's brain tissue compared with healthy tissue, and diseased cells tended to carry more of them overall. Every microprotein in the atlas was independently confirmed with mass spectrometry, a chemical technique that detects the actual peptide fragments a cell has produced, rather than relying on genetic sequence predictions alone. That confirmation step, the researchers say, is what separates the new catalog from earlier, more speculative lists of possible short proteins.

How researchers found a hidden layer of the genome

The discovery leaned on ShortStop, a machine-learning tool the same Salk lab published last year that scans genetic databases for short open reading frames likely to produce real, functional microproteins, then filters out sequences that resemble random genetic noise rather than working genes. Applying that tool to existing transcriptomic and mass-spectrometry data from nearly 500 brains let the team, led by senior author Alan Saghatelian and postdoctoral researcher Brendan Miller, reprocess information that had already been collected for other purposes and pull new findings out of data sets other scientists had already moved past.

"There is sometimes an assumption that we know everything about our genome," Saghatelian has said of the broader microprotein effort, a view that echoes the group's earlier work arguing that thousands of small, functional proteins have been overlooked because of how the genome was first annotated decades ago. The new atlas, the researchers say, gives other labs a straightforward way to check whether any gene of interest also produces a hidden microprotein counterpart that conventional databases never flagged.

A new suspect inside the brain's immune cells

The most striking result involved microglia, the resident immune cells that patrol the brain, clear cellular debris, and — as the National Institute on Aging has documented in separate research on the cells — become increasingly dysfunctional with age and in neurodegenerative disease. The Salk team generated its own mass-spectrometry data on microglia and found that, within one particular stretch of genetic code capable of producing either a conventional protein or a microprotein, the cells were predominantly making the microprotein rather than the longer, already-known protein.

When the researchers experimentally deleted the gene responsible in cultured microglia, the cells' mitochondria — the structures that generate cellular energy — became impaired. That result suggests the microprotein plays a functional role in keeping microglial energy production running normally, and that its disruption could contribute to the kind of immune-cell dysfunction long observed in Alzheimer's brains, though the study stops short of establishing that the microprotein directly causes disease in people.

"Our atlas allows scientists to systemically investigate microproteins in aging and neurodegeneration, which should bring us closer to understanding and tackling diseases like Alzheimer's or Parkinson's," said Alan Saghatelian, the study's senior author.

Who stands to benefit

The immediate beneficiaries are researchers rather than patients. The Salk team has made the full atlas publicly downloadable, and Miller said the goal was to hand other labs "an entirely new database" they can mine to reinterpret genes they already study, according to the EurekAlert summary of the release. Because the underlying tissue and sequencing data already existed in public repositories, the same approach could in principle be applied to other neurodegenerative conditions, including Parkinson's disease, without collecting new brain donations.

• 480 postmortem frontal-cortex samples analyzed, split between Alzheimer's and non-Alzheimer's brains
• 1,067 previously uncharacterized microproteins identified and confirmed by mass spectrometry
• One microprotein, when its gene was deleted in microglia, impaired the cells' mitochondrial energy production

For the estimated 7.4 million Americans age 65 and older currently living with Alzheimer's, according to the Alzheimer's Association's 2026 facts-and-figures report, the practical payoff remains distant. The paper identifies a molecular association between one microprotein and microglial energy metabolism; it does not test a drug, and the researchers have not proposed the microprotein as a therapeutic target in humans. Coverage of the study in Nature's own news section and in Medical Xpress both frame the atlas as a resource that widens the list of mechanisms scientists can investigate, rather than as a finished explanation of the disease.

What happens next

Outside researchers are expected to use the atlas to search for microproteins tied to their own genes of interest, and the Salk group has signaled it intends to apply the same ShortStop-based approach to other tissue types and diseases where small proteins have historically been missed by standard genomic tools. Validating whether the microglial microprotein actually affects Alzheimer's progression in living animals, rather than in cultured cells, would be a necessary next step before any therapeutic implications could be seriously explored. The study was funded by the National Institutes of Health and the Clayton Medical Research Foundation, and the full data set has been released for other laboratories to download and test against their own genes of interest.